azomycin has been researched along with pa 824 in 178 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 31 (17.42) | 29.6817 |
2010's | 97 (54.49) | 24.3611 |
2020's | 50 (28.09) | 2.80 |
Authors | Studies |
---|---|
Anderson, SW; Arain, TM; Baker, WR; Barry, CE; Kreiswirth, BN; Langhorne, MH; McMurray, DN; Sherman, DR; Stover, CK; Towell, JA; VanDevanter, DR; Warrener, P; Yuan, Y | 1 |
Bae, YM; Bair, TB; Choi, KP; Daniels, L | 1 |
Choi, KP; Daniels, L; Kendrick, N | 1 |
Doi, N | 1 |
Bishai, W; Grosset, J; Lounis, N; Nuermberger, E; Rosenthal, I; Tyagi, S; Williams, K; Yoshimatsu, T | 1 |
Driscoll, DK; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Reynolds, RC; Rose, JD; Tompkins, NM | 1 |
Ahmad, K | 1 |
Albert, TJ; Barry, CE; Boshoff, H; Daniels, L; Dick, T; Dowd, CS; Manjunatha, UH; Norton, JE; Pang, SS; Zhang, L | 1 |
Andries, K; Chauffour, A; Jarlier, V; Ji, B | 1 |
Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C | 1 |
Almeida, D; Bishai, WR; Grosset, JH; Nuermberger, E; Peloquin, CA; Rosenthal, I; Tyagi, S; Williams, KN | 1 |
Barry, CE; Dowd, CS; Krahenbuhl, JL; Lahiri, R; Manjunatha, UH; Randhawa, B | 1 |
Bloomer, WD; McNeil, MR; Papadopoulou, MV | 1 |
Zhang, Y | 1 |
Coates, AR; Hu, Y; Mitchison, DA | 1 |
Almeida, D; Grosset, JH; Nuermberger, E; Rosenthal, I; Tasneen, R; Tyagi, S; Williams, KN | 1 |
Barry, CE; Dowd, CS; Goodwin, MB; Keller, TH; Knox, JE; Li, X; Lipinski, CA; Manjunatha, UH | 1 |
Baker, EN; Bashiri, G; Moreland, NJ; Squire, CJ | 1 |
Nau, JY | 1 |
Anderson, RF; Boyd, M; Denny, WA; Maroz, A; Palmer, BD; Shinde, SS | 1 |
Mancera, RL; Rivers, EC | 1 |
Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K | 1 |
Nathan, C | 1 |
Barry, CE; Boshoff, HI; Dowd, CS; Ha, YH; Jiricek, J; Kang, S; Keller, TH; Kim, P; Ledwidge, R; Lee, IY; Manjunatha, U; Niyomrattanakit, P; Singh, R; Zhang, L | 1 |
Anderson, RF; Blaser, A; Denny, WA; Franzblau, SG; Ma, Z; Palmer, BD; Shinde, SS; Thompson, AM | 1 |
Edwards, DA; Elbert, KJ; Garcia-Contreras, L; Hickey, AJ; Peloquin, CA; Sung, JC; Verberkmoes, JL | 1 |
Ginsberg, AM; Laurenzi, MW; Rouse, DJ; Spigelman, MK; Whitney, KD | 2 |
Blaser, A; Denny, WA; Franzblau, SG; Kmentova, I; Ma, Z; Palmer, BD; Sutherland, HS; Thompson, AM; Wan, B; Wang, Y | 5 |
Anderson, RF; Denny, WA; Franzblau, SG; Ma, Z; Maroz, A; Palmer, BD; Shinde, SS | 1 |
Edwards, DA; Elbert, KJ; Garcia-Contreras, L; Hickey, AJ; Muttil, P; Padilla, D; Sung, JC; Telko, M; Verberkmoes, JL | 1 |
Dawson, R; Diacon, AH; Donald, PR; Ginsberg, AM; Hanekom, M; Laurenzi, MW; Maritz, SJ; Narunsky, K; Rouse, DJ; Spigelman, MK; van Niekerk, C; Venter, A; Whitney, K | 1 |
Cole, ST; Dhar, N; Ha, YH; Hartkoorn, RC; Sala, C; Schneider, P; Zhang, M | 1 |
Marsini, MA; Reider, PJ; Sorensen, EJ | 1 |
Ahmad, Z; Derendorf, H; Ginsberg, A; Grosset, JH; Nuermberger, EL; Peloquin, CA; Singh, RP; Tyagi, S | 1 |
Anderson, RF; Baker, EN; Bashiri, G; Denny, WA; Dogra, M; Helsby, NA; O'Toole, R; Palmer, BD; Shinde, SS; Tingle, MD | 1 |
Hutson, S | 1 |
Barry, CE; Bollo, S; Boshoff, HI; Dowd, CS; Kang, S; Núñez-Vergara, LJ; Squella, JA; Zhang, L | 1 |
Denny, WA; Palmer, BD | 1 |
Degani, MS; Tawari, NR | 1 |
Barry, CE; Boshoff, HI; Cherian, J; Choi, I; Dartois, V; Dick, T; Goodwin, M; Ha, YH; Jiricek, J; Keller, TH; Lakshminarayana, SB; Lee, YS; Manjunatha, UH; Mukherjee, T; Nayyar, A; Niyomrattanakit, P; Ravindran, S; Singh, R | 1 |
Ginsberg, A | 1 |
Cui, Z; Fu, X; Hu, Z; Jin, K; Li, Y; Wu, W; Yu, G; Zhang, L | 1 |
Archer, JA; Baù, D; Feuerriegel, S; Köser, CU; Marti-Renom, MA; Niemann, S; Rüsch-Gerdes, S; Summers, DK | 1 |
Andries, K; Li, SY; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Tasneen, R; Taylor, D; Williams, KN | 1 |
Barry, CE; Boshoff, HI; Cherian, J; Dick, T; Dowd, CS; Gurumurthy, M; Lee, YS; Manjunatha, UH; Mukherjee, T; Nayyar, A; Niyomrattanakit, P; Singh, R; Tay, JA | 1 |
Bishai, WR; Davis, SL; Harper, J; Jain, SK; Kramnik, I; Nuermberger, EL; Pomper, MG; Skerry, C; Tasneen, R; Weir, M | 1 |
Campbell, S; Jakubiec, W; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS | 1 |
Becker, P; Dawson, R; Diacon, AH; Donald, PR; du Bois, J; Erondu, N; Ginsberg, AM; Narunsky, K; Spigelman, MK; van Niekerk, C; Venter, A | 1 |
Roehr, B | 1 |
Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K | 1 |
Campos-Rivera, MP; Cole, ST; Gonzalez-Martinez, NA; Ocampo-Candiani, J; Vera-Cabrera, L | 1 |
Becker, P; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Mendel, CM; Spigelman, MK; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F; Winter, H | 1 |
Kmietowicz, Z | 1 |
Cole, ST; Hartkoorn, RC; Lechartier, B | 1 |
Dawson, R; Diacon, A | 1 |
Egizi, E; Erondu, N; Everitt, D; Ginsberg, A; Pauli, E; Rouse, DJ; Severynse-Stevens, D; Winter, H | 1 |
Alsultan, A; Belchis, DA; Dutta, NK; Gniadek, TJ; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML | 1 |
Egizi, E; Erondu, N; Everitt, D; Ginsberg, A; Pauli, E; Whitney, K; Winter, H | 1 |
Anand, RS; Paramasivan, CN; Somasundaram, S; Venkatesan, P | 1 |
Mukhopadhyay, B; Purwantini, E | 1 |
Jeong, BH; Koh, WJ; Kwon, YS | 1 |
Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Seddon, JA | 1 |
Diao, C; Liang, L; Liu, X; Wang, L; Xu, Y; Zhang, J; Zhang, S | 1 |
Allen, R; Aweeka, F; Bao, J; Cramer, Y; Dooley, KE; Haas, DW; Koletar, SL; Luetkemeyer, AF; Marzan, F; Murray, S; Park, JG; Savic, R; Sutherland, D | 1 |
Barry, CE; Blasco, F; Boshoff, HI; Cherian, J; Dick, T; Goh, A; Gurumurthy, M; Ho, PC; Jiricek, J; Lakshminarayana, SB; Manjunatha, UH; Nanjundappa, M; Nayyar, A; Ravindran, S; Singh, R | 1 |
Dutta, NK; Karakousis, PC | 1 |
Cho, S; Franzblau, SG; Kim, Y; Lu, Y; Ma, Z; Mdluli, K; Upton, AM; Wang, B; Wang, Y; Xu, J; Yang, TJ | 1 |
Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K | 1 |
Chang, KC; Heyckendorf, J; Lange, C; Olaru, ID; von Groote-Bidlingmaier, F; Yew, WW | 1 |
Burger, DA; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Hutchings, J; Mendel, CM; Schall, R; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F | 1 |
Gund, MG; Mangu, NK; Nair, V; Okello, MO; Seo, BI | 1 |
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F | 1 |
Migliori, GB; Sotgiu, G | 1 |
A Bester, L; Bratkowska, D; Govender, T; Kruger, HG; Maguire, GE; Shobo, A; Singh, S | 1 |
Inturi, B; Pujar, GV; Purohit, MN | 1 |
Bifani, P; Chua, A; Ghode, P; Haver, HL; Lakshminarayana, SB; Mathema, B; Singhal, A; Wintjens, R | 1 |
Arora, G; Kang, YG; Lee, IY; Park, CY; Shin, H; Singh, R; Yu, CM | 1 |
Baijnath, S; Bester, LA; Bratkowska, D; Govender, T; Kruger, HG; Naicker, T; Naiker, S; Shobo, A; Singh, SD; Somboro, AM | 1 |
Ballinger, E; Glasheen, J; Gold, B; Ling, Y; Nathan, C; Quezada, LL; Roberts, J; Somersan-Karakaya, S; Warren, JD; Warrier, T | 1 |
Franzblau, SG; Gutka, HJ; Movahedzadeh, F; Wang, Y | 1 |
Betoudji, F; Converse, PJ; Dartois, V; Li, SY; Mdluli, KE; Mendel, CM; Nuermberger, EL; Tasneen, R; Tyagi, S; Williams, K; Yang, T | 1 |
Duan, H; Liang, L; Liu, X; Ma, Y; Wang, L; Wang, Q; Yao, J; Zhang, R; Zhang, S; Zhou, X | 1 |
Bruhn, DF; Lee, RE; Lenaerts, AJ; Liu, J; Scherman, MS; Singh, AP; Yang, L | 1 |
Das, SC; Krittaphol, W; Momin, MAM; Thien, SJ | 1 |
Koniordou, M; Patterson, S; Seifert, K; Wyllie, S | 1 |
Cohen, J | 1 |
Mendel, C; Murray, S; Spigelman, M | 1 |
Anderson, RF; Blaser, A; Chatelain, E; Denny, WA; Franzblau, SG; Launay, D; Ma, Z; Maes, L; Palmer, BD; Shinde, SS; Thompson, AM; Wan, B; Wang, Y | 1 |
Ahmed, Z; Bhagat, A; Kour, G; Singh, PP | 1 |
Converse, PJ; Li, SY; Mdluli, K; Nuermberger, EL; Soni, H; Tasneen, R; Tyagi, S | 1 |
Li, DG; Ren, ZX | 1 |
Alland, D; Bajaj, A; Dhiman, R; Gosain, TP; Hwang, YK; Jung, MG; Kidwai, S; Kumar, P; Kumar, S; Lee, IY; Mawatwal, S; Park, CY; Singh, R; Song, CS; Tiwari, P | 1 |
Bacchi, CJ; Braillard, S; Chatelain, E; Denny, WA; Gaukel, E; Launay, D; Maes, L; Marshall, AJ; Mowbray, CE; Thompson, AM; Wring, SA; Yarlett, N | 1 |
Connell, N; Dartois, V; Freundlich, JS; Ho, HP; Inoyama, D; Kandasamy, S; Kumar, P; Occi, J; Paget, SD; Perryman, AL; Russo, R; Singleton, E; Tuckman, M; Zimmerman, MD | 1 |
Feng, T; Jing, J; Liu, X; Mi, L; Shen, X; Wang, L; Zhang, R; Zhang, S; Zhao, J; Zhou, N | 1 |
Aguilar-Ayala, DA; Cnockaert, M; Gonzalez-Y-Merchand, J; Martin, A; Palomino, JC; Vandamme, P | 1 |
Bujalska-Zadrozny, M; Pstragowski, M; Zbrzezna, M | 1 |
Baillie, L; Baptista, R; Beckmann, M; Fazakerley, DM; Mur, LAJ | 1 |
Lyons, MA | 3 |
Baijnath, S; Govender, T; Kruger, HG; Makatini, MM; Naicker, T; Pamreddy, A; Shobo, A | 1 |
Arbex, MA; D'Ambrosio, L; Dalcolmo, M; Duarte, R; Gaga, M; Migliori, GB; Munoz-Torrico, M; Rendon, A; Silva, DR; Tiberi, S; Visca, D; Zumla, A | 1 |
Loganathan, U; Mukhopadhyay, B; Purwantini, E | 1 |
Chaudhari, HK; Pahelkar, A | 1 |
Borkute, R; Choudhari, AS; Degani, MS; Krishna, VS; Mali, HM; Sabale, SS; Sarkar, D; Sriram, D | 1 |
de Miranda Silva, C; Drusano, GL; Hajihosseini, A; Louie, A; Myrick, J; Nole, J; Schmidt, S | 1 |
Ang, CW; Avery, VM; Blaskovich, MAT; Butler, MS; Cooper, MA; Debnath, A; Hahn, HJ; Jarrad, AM; Jones, AJ; Karoli, T; Pelingon, R; Sykes, ML; Tan, L; West, NP; Woods, K | 1 |
Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD | 1 |
Chu, N; Huang, H; Jing, W; Pang, Y; Shang, Y; Wang, F; Wen, S; Xue, Y; Zhang, T; Zong, Z | 1 |
Fattorini, L; Giannoni, F; Iacobino, A; Pardini, M; Piccaro, G | 1 |
Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH | 1 |
Billard, T; Dickson, C; Gampe, CM; Ghiazza, C; Tlili, A | 1 |
Ceyssens, PJ; Coppee, JY; Legendre, R; Mathys, V; Sismeiro, O; Sury, A; Van den Bossche, A; Varet, H | 1 |
Everitt, D; Nedelman, JR; Salinger, DH; Subramoney, V | 1 |
Dheda, K; Dooley, KE; Furin, J; Gumbo, T; Maartens, G; Murray, M; Nardell, EA; Warren, RM | 1 |
Cook-Scalise, S; Denkinger, CM; Dowdy, DW; Kendall, EA; Malhotra, S | 1 |
Burki, T | 1 |
Keam, SJ | 1 |
Mushtaq, A | 1 |
Bendet, P; Berg, A; Cirrincione, K; Deshpande, D; Gumbo, T; Hanna, D; Hermann, D; Magombedze, G; Martin, K; Romero, K; Srivastava, S; van Zyl, J | 1 |
Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E | 1 |
Furin, J; McKenna, L | 1 |
Aher, RB; Sarkar, D | 1 |
Afriat-Jurnou, L; Ahmed, FH; Almeida, DV; Aung, HL; Beatson, SA; Cook, GM; Forde, BM; Greening, C; Hards, K; Harold, LK; Jackson, CJ; Lee, BM; Mohamed, AE; Nuermberger, EL; Pidot, SJ; Stinear, TP; Taylor, MC; West, NP | 1 |
de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A | 1 |
Bateson, A; Conradie, F; Crook, AM; Diacon, AH; Egizi, E; Everitt, D; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Moreira, J; Ngubane, N; Olugbosi, M; Spigelman, M; Timm, J; Van Niekerk, C; Wills, GH | 1 |
Farhat, M; Kadura, S; King, N; Köser, CU; Nakhoul, M; Theron, G; Zhu, H | 1 |
Bigelow, KM; Chang, YS; Dooley, KE; Nuermberger, EL; Tasneen, R | 1 |
Hussar, DA | 1 |
Bashiri, G; Ioerger, T; Lanoix, JP; Lee, J; Li, SY; Nuermberger, E; Rifat, D; Sacchettini, J; Shah, K | 1 |
Everitt, D; Li, M; Mendel, CM; Nedelman, JR; Salinger, DH; Spigelman, M; Subramoney, V; Wade, K; Woolson, R | 1 |
Chopra, S; Dasgupta, A; Thakare, R | 1 |
El-Amin, W; Everitt, D; Li, M; Makhene, MK; Nedelman, J; Osborn, B; Saviolakis, GA; Yang, TJ | 1 |
Castel, S; Dawson, R; Dooley, KE; Ignatius, EH; Joubert, A; Kellermann, T; Malo, A; Norman, J; Wiesner, L | 1 |
Nambiar, S; Schumann, K; Walinsky, S | 1 |
Begum, A; Fatima, N; Heba, SF; Parveen, U; Rafi, R; Sultana, S | 1 |
Biswas, S; Deb, U | 1 |
Pregnolato, M; Taccani, M; Terreni, M | 1 |
Abdel-Rahman, SM; Mirzayev, F; Stancil, SL | 1 |
de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A | 1 |
Ang, CW; Blaskovich, MAT; Cooper, MA; Popat, A; Qu, Z; Tan, L; West, NP | 1 |
Campino, S; Clark, TG; Gomes, P; Gómez-González, PJ; Hibberd, ML; Napier, G; Perdigao, J; Phelan, JE; Portugal, I; Puyen, ZM; Santos-Lazaro, D; Viveiros, M | 1 |
He, W; Li, F; Shen, C; Wang, S; Wang, Y; Xia, H; Zhao, B; Zhao, Y; Zheng, H | 1 |
Avaliani, Z; Conradie, F; Cook-Scalise, S; Everitt, D; Garfin, AMC; Gomez, GB; Juneja, S; Kiria, N; Lomtadze, N; Malhotra, S; Ndjeka, N; Siapka, M; Spigelman, M; Vassall, A | 1 |
Howell, P; Mvuna, N; Olugbosi, M; Upton, C | 1 |
Almoslem, M; Drusano, GL; Duncanson, B; Kim, S; Louie, A; Myrick, J; Neely, M; Nole, J; Peloquin, CA; Scanga, CA; Schmidt, S; Yamada, W | 1 |
Cook-Scalise, S; Edo, P; Gebhard, A; Juneja, S; Kadyrov, A; Lawanson, A; Malhotra, S; Mambetova, E; Mulder, C; Pambudi, I; Rupert, S; Setiawan, E; Sohn, H; Sugiharto, J; Useni, S; van den Hof, S | 1 |
Bax, HI; De Steenwinkel, JEM; Lenaerts, A; Mudde, SE; Upton, AM | 1 |
Andres, S; Bateson, A; Borroni, E; Cirillo, DM; Dippenaar, A; Feuerriegel, S; Ghodousi, A; Groenheit, R; Kohl, TA; Köser, CU; Kranzer, K; Machado, D; Maurer, FP; McHugh, TD; Merker, M; Niemann, S; Ortiz Canseco, J; Sirgel, F; Sun, E; Timm, J; Toro, JC; Utpatel, C; Viveiros, M; Warren, RM; Werngren, J; Wijkander, M; Witney, AA | 1 |
Shaheer, M; Singh, R; Sobhia, ME | 1 |
Hui, AM; Li, K; Liu, Y; Lu, Z; Tan, Y; Wei, G; Yang, B | 1 |
Betteridge, M; Boekelheide, K; Everitt, D; Nedelman, J; Olugbosi, M; Smith, E; Spigelman, M; Sun, E | 1 |
Alffenaar, J; Burke, A; Denholm, J | 1 |
Devaleenal, B; Mandal, S; Mattoo, S; Padmapriyadarsini, C; Parmar, M; Ponnuraja, C; Ramraj, B; Singla, R | 1 |
Bagdasaryan, TR; Bateson, A; Borisov, S; Conradie, F; Crook, AM; Egizi, E; Everitt, D; Fabiane, SM; Foraida, S; Holsta, A; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Mikiashvili, L; Ngubane, N; Olugbosi, M; Samoilova, A; Skornykova, S; Spigelman, M; Sun, E; Timm, J; Tudor, E; Tweed, CD; Variava, E; Wills, GH; Yablonskiy, P | 1 |
Ashkin, D; Goswami, ND; Haley, CA | 1 |
Juturu, RR; Surapuraju, PKR | 1 |
Bekele, F; Fekadu, G; Fetensa, G; Tolossa, T; Turi, E | 1 |
Groenheit, R; Grönfors Seeth, C; Karlsson Lindsjö, O; Mansjö, M; Werngren, J | 1 |
Barnes, G; Dawson, R; Dooley, KE; Dorman, SE; Friedman, A; Gupte, N; Hendricks, B; Ignatius, EH; Narunsky, K; Smit, T; Whitelaw, C | 1 |
Bahr, M; Brosnan, MK; Chen, X; Dannals, RF; De Jesus, P; Erice, C; Flavahan, K; Holt, DP; Jain, SK; Kim, J; Lodge, MA; Mota, F; Ordonez, AA; Peloquin, CA; Ruiz-Bedoya, CA; Tucker, EW | 1 |
Nahid, P; Velásquez, GE | 1 |
Aarnoutse, R; Andres, S; Choong, E; Decosterd, LA; Dreyer, V; John, A; Kalsdorf, B; Koehler, N; König, C; Krieger, D; Kuhns, M; Lange, C; Maurer, FP; Merker, M; Niemann, S; Peloquin, CA; Sanchez Carballo, PM; Schaub, D; Schön, T; Schönfeld, N; Verougstraete, N; Verstraete, AG; Werngren, J; Wicha, SG; Zur Wiesch, PA | 1 |
Guo, T; Mehta, K; van der Graaf, PH; van Hasselt, JGC | 1 |
Betoudji, F; Converse, PJ; Fotouhi, N; Lee, J; Li, SY; Mdluli, K; Nuermberger, EL; Upton, A | 1 |
Abrahams, KA; Bashiri, G; Batt, SM; Besra, GS; Gurcha, SS; Veerapen, N | 1 |
Alffenaar, JC; Anthony, RM; Nguyen, QH; Nguyen, TNT; Nguyen, TVA; Vu, DH | 1 |
Abdalla, BJ; Abramovitch, RB; Albrecht, VJ; Eke, IE; Haiderer, ER; Murdoch, HM; Williams, JT | 1 |
Ahrenstorf, G; Friesen, I; Joean, O; Kuhns, M; Picksak, G; Ringshausen, FC; Trauth, J; Welte, T | 1 |
22 review(s) available for azomycin and pa 824
Article | Year |
---|---|
[Anti-tuberculosis drugs].
Topics: 4-Quinolones; Anti-Infective Agents; Antitubercular Agents; Chlorpromazine; Drug Delivery Systems; Drug Design; Drug Resistance, Multiple, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Rifamycins | 2003 |
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2007 |
PA-824.
Topics: Animals; Antitubercular Agents; Humans; Nitroimidazoles; Treatment Outcome; Tuberculosis | 2008 |
New anti-tuberculosis drugs with novel mechanisms of action.
Topics: Adamantane; Animals; Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Quinolines; Structure-Activity Relationship; Tuberculosis, Pulmonary | 2008 |
The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies.
Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Structure-Activity Relationship; Tuberculosis | 2010 |
PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Molecular Structure; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis, Pulmonary | 2013 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Managing multidrug-resistant tuberculosis in children: review of recent developments.
Topics: Antitubercular Agents; Child; Child, Preschool; Directly Observed Therapy; Drug Administration Schedule; Ethionamide; Fluoroquinolones; Humans; Infant; Moxifloxacin; Nitroimidazoles; Practice Guidelines as Topic; Prevalence; Pyrazinamide; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2014 |
Novel drugs against tuberculosis: a clinician's perspective.
Topics: Adamantane; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarylquinolines; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Nitroimidazoles; Oxazoles; Oxazolidinones; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
ADVANCES IN PHARMACOTHERAPY OF TUBERCULOSIS.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Humans; Nitroimidazoles; Oxazolidinones; Tuberculosis, Multidrug-Resistant | 2017 |
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Repositioning; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles | 2018 |
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease.
Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles | 2019 |
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Linezolid; Nitroimidazoles; Oxazoles; Periodicals as Topic; Pulmonary Medicine; Societies, Medical; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
Pretomanid: First Approval.
Topics: Anti-Bacterial Agents; Antifungal Agents; Drug Approval; Humans; Nitroimidazoles; Tuberculosis; United States | 2019 |
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pharmaceutical Preparations; Tuberculosis, Multidrug-Resistant | 2020 |
Pretomanid: A novel therapeutic paradigm for treatment of drug resistant tuberculosis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Pretomanid: The latest USFDA-approved anti-tuberculosis drug.
Topics: Antitubercular Agents; Drug Approval; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; United States; United States Food and Drug Administration | 2021 |
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cefiderocol; Cephalosporins; Chemistry, Pharmaceutical; Clostridioides difficile; Clostridium Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Meropenem; Neisseria gonorrhoeae; Nitroimidazoles; Sisomicin; Tetracyclines | 2021 |
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Pretomanid for tuberculosis: a systematic review.
Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Pretomanid development and its clinical roles in treating tuberculosis.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice.
Topics: Animals; Antitubercular Agents; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
19 trial(s) available for azomycin and pa 824
Article | Year |
---|---|
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nitroimidazoles; Young Adult | 2009 |
Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects.
Topics: Adult; Antitubercular Agents; Blood Urea Nitrogen; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Nitroimidazoles; Renal Plasma Flow, Effective; Young Adult | 2009 |
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.
Topics: Adult; Antitubercular Agents; Colony Count, Microbial; Culture Media; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mycobacterium tuberculosis; Nitroimidazoles; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2010 |
Phase II dose-ranging trial of the early bactericidal activity of PA-824.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult | 2012 |
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Prospective Studies; Pyrazinamide; Quinolines; Sputum; Tuberculosis, Pulmonary; Young Adult | 2012 |
Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects.
Topics: Adolescent; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Midazolam; Middle Aged; Nitroimidazoles; Time Factors; Young Adult | 2013 |
Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects.
Topics: Administration, Oral; Adult; Antitubercular Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Dietary Fats; Drug Administration Schedule; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Nitroimidazoles | 2013 |
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
Topics: Adult; Alkynes; Antitubercular Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Middle Aged; Nitroimidazoles; Pharmacogenetics; Rifampin; Ritonavir; Young Adult | 2014 |
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.
Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2015 |
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul
Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2015 |
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2019 |
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda | 2019 |
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Bacterial Load; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Intention to Treat Analysis; Linezolid; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2020 |
Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers.
Topics: Adolescent; Adult; Antitubercular Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Nitroimidazoles; Young Adult | 2021 |
Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design.
Topics: Adult; Antitubercular Agents; Colony-Forming Units Assay; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Nitroimidazoles; Safety; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2021 |
Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study.
Topics: Adult; Area Under Curve; Asian People; China; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Humans; Hyperbilirubinemia; Male; Nitroimidazoles; Young Adult | 2022 |
Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study
Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2022 |
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Topics: Aminoglycosides; Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Rifampin; Risk Assessment; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2023 |
137 other study(ies) available for azomycin and pa 824
Article | Year |
---|---|
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Drug Resistance, Multiple; Guinea Pigs; Lipids; Metronidazole; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Tuberculosis | 2000 |
Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG.
Topics: Antitubercular Agents; Bacterial Proteins; Coenzymes; DNA Transposable Elements; Drug Resistance, Bacterial; Enzymes; Genes, Bacterial; Genetic Complementation Test; Multigene Family; Mutagenesis, Insertional; Mycobacterium bovis; Nitroimidazoles; Operon; Riboflavin; Sequence Analysis, DNA; Transcription, Genetic | 2001 |
Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis.
Topics: Cloning, Molecular; DNA Transposable Elements; Escherichia coli; Genes, Bacterial; Genetic Complementation Test; Histidine; Molecular Sequence Data; Multigene Family; Mutagenesis, Insertional; Mycobacterium bovis; Nitroimidazoles; Riboflavin | 2002 |
Tuberculosis: new drug class investigated through public-private partnership.
Topics: Antitubercular Agents; Cooperative Behavior; Humans; Nitroimidazoles; Private Sector; Public Sector; Tuberculosis | 2000 |
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Random Allocation; Tuberculosis, Pulmonary | 2005 |
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Specific Pathogen-Free Organisms; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2005 |
New tuberculosis drug enters human trials.
Topics: Antitubercular Agents; Clinical Trials as Topic; Humans; Nitroimidazoles; Tuberculosis | 2005 |
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis.
Topics: Bacterial Proteins; DNA Transposable Elements; Drug Resistance, Bacterial; Genome, Bacterial; Glucosephosphate Dehydrogenase; Molecular Sequence Data; Molecular Structure; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Phenotype | 2006 |
NIAID researchers make key discovery in development of TB drug candidate.
Topics: Antitubercular Agents; Drug Design; Drug Resistance, Bacterial; Mycobacterium tuberculosis; National Institutes of Health (U.S.); Nitroimidazoles; United States | 2006 |
Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.
Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Diarylquinolines; Female; Fluoroquinolones; Leprosy; Linezolid; Mice; Moxifloxacin; Mycobacterium leprae; Nitroimidazoles; Oxazolidinones; Quinolines | 2006 |
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors | 2006 |
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Rifampin; Secondary Prevention; Time Factors; Tuberculosis, Pulmonary | 2006 |
Mycobacterium leprae is naturally resistant to PA-824.
Topics: Animals; Culture Media; Disease Models, Animal; Drug Resistance, Bacterial; Leprosy; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Microbial Sensitivity Tests; Mycobacterium leprae; Nitroimidazoles | 2006 |
NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Imidazoles; Inhibitory Concentration 50; Mycobacterium tuberculosis; Nitroimidazoles; Prodrugs; Quinolines; Time Factors; Vero Cells | 2007 |
Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Time Factors | 2008 |
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.
Topics: Antitubercular Agents; Crystallography, X-Ray; Drug Resistance, Bacterial; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Stereoisomerism; Structure-Activity Relationship | 2008 |
Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding.
Topics: Amino Acid Sequence; Antitubercular Agents; Crystallography, X-Ray; Glucosephosphate Dehydrogenase; Kinetics; Models, Chemical; Molecular Conformation; Molecular Sequence Data; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Protein Binding; Protein Conformation; Sequence Homology, Amino Acid; Substrate Specificity | 2008 |
[Some new antitubercular agents].
Topics: Acetamides; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Oxazoles; Oxazolidinones; Quinolines | 2008 |
Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Magnetic Resonance Spectroscopy; Models, Molecular; Nitroimidazoles; Oxidation-Reduction; Solutions; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Water | 2008 |
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitroimidazoles; Pyrazinamide; Recurrence; Rifampin; Tuberculosis, Pulmonary | 2008 |
Microbiology. An antibiotic mimics immunity.
Topics: Anaerobiosis; Antitubercular Agents; Glucosephosphate Dehydrogenase; Humans; Mycobacterium tuberculosis; Nitric Oxide; Nitroimidazoles; Nitroreductases; Reactive Nitrogen Species; Riboflavin; Tuberculosis | 2008 |
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.
Topics: Anaerobiosis; Antitubercular Agents; Glucosephosphate Dehydrogenase; Immunity, Innate; Mycobacterium tuberculosis; Nitric Oxide; Nitric Oxide Donors; Nitroimidazoles; Nitroreductases; Oxidation-Reduction; Prodrugs; Reactive Nitrogen Species; Riboflavin; Stereoisomerism | 2008 |
Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxidation-Reduction; Vero Cells | 2009 |
Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.
Topics: Administration, Inhalation; Aerosols; Animals; Antitubercular Agents; Guinea Pigs; Male; Nitroimidazoles; Powders | 2009 |
Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Mice; Mice, Inbred BALB C; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Stereoisomerism; Structure-Activity Relationship | 2010 |
Release of nitrite from the antitubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solvent.
Topics: Aerobiosis; Antitubercular Agents; Electron Transport; Hypoxia; Mass Spectrometry; Mycobacterium tuberculosis; Nitriles; Nitrites; Nitrobenzenes; Nitroimidazoles; Pulse Radiolysis; Reactive Nitrogen Species; Solvents; Spectrophotometry, Ultraviolet; Water | 2010 |
Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.
Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Antitubercular Agents; Chemistry, Pharmaceutical; Colony Count, Microbial; Disease Models, Animal; Extensively Drug-Resistant Tuberculosis; Guinea Pigs; Humans; Latent Tuberculosis; Lung; Male; Nitroimidazoles; Particle Size; Powders; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2010 |
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Isoniazid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Streptomycin; Thienamycins | 2010 |
A concise and convergent synthesis of PA-824.
Topics: Antitubercular Agents; Drug Resistance, Multiple; Hydrolysis; Kinetics; Nitroimidazoles; Stereoisomerism | 2010 |
PA-824 exhibits time-dependent activity in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Female; Humans; Mice; Nitroimidazoles; Tuberculosis | 2011 |
Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.
Topics: Antitubercular Agents; Base Sequence; Biotransformation; DNA Primers; Humans; Liver; Mass Spectrometry; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Subcellular Fractions | 2011 |
Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred BALB C; Nitroimidazoles; Oxazines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tuberculosis | 2010 |
Half-century-old TB drugs get a facelift in new cocktails.
Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis | 2010 |
The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824.
Topics: Antitubercular Agents; Electrochemistry; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxidation-Reduction; Tuberculosis | 2011 |
Pharmacophore modeling and density functional theory analysis for a series of nitroimidazole compounds with antitubercular activity.
Topics: Antitubercular Agents; Drug Design; Humans; Models, Biological; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Quantitative Structure-Activity Relationship; Quantum Theory; Tuberculosis | 2011 |
Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Evaluation, Preclinical; Humans; Kinetics; Metabolic Clearance Rate; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Prodrugs; Structure-Activity Relationship; Substrate Specificity; Tuberculosis | 2011 |
Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).
Topics: Acute Disease; Animals; Antitubercular Agents; Chronic Disease; Ethers; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Stereoisomerism; Structure-Activity Relationship; Tuberculosis, Pulmonary | 2011 |
The TB Alliance: overcoming challenges to chart the future course of TB drug development.
Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Diarylquinolines; Drug Evaluation, Preclinical; Fluoroquinolones; Humans; Models, Organizational; Moxifloxacin; Nitroimidazoles; Quinolines; Tuberculosis | 2011 |
Integrative analysis of transcriptome and genome indicates two potential genomic islands are associated with pathogenesis of Mycobacterium tuberculosis.
Topics: Base Sequence; Down-Regulation; Gene Expression Profiling; Genomic Islands; Lipids; Molecular Sequence Data; Mycobacterium tuberculosis; Nitroimidazoles | 2011 |
Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Genetic Variation; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Polymorphism, Single Nucleotide; Sequence Analysis, DNA | 2011 |
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Secondary Prevention; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2011 |
Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.
Topics: Antitubercular Agents; Cloning, Molecular; Flavins; Kinetics; Mycobacterium tuberculosis; Nitric Oxide; Nitroimidazoles; Nitroreductases; Oxazoles; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity | 2012 |
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Topics: Acute Disease; Amides; Animals; Antitubercular Agents; Biological Availability; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carbamates; Chronic Disease; Dogs; Humans; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Piperazines; Rats; Solubility; Stereoisomerism; Structure-Activity Relationship; Tuberculosis, Pulmonary; Urea | 2012 |
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions.
Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Fluoroquinolones; Gene Expression Profiling; Genes, Bacterial; Granuloma; Hypoxia; Immunohistochemistry; Male; Mice; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Positron-Emission Tomography; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis | 2012 |
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Time Factors | 2012 |
Trial tests new combination of drugs to treat tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Research Support as Topic; Tuberculosis; United States | 2012 |
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2012 |
In vitro activities of the new antitubercular agents PA-824 and BTZ043 against Nocardia brasiliensis.
Topics: Antitubercular Agents; Microbial Sensitivity Tests; Nitroimidazoles; Nocardia | 2012 |
New drug combination for TB is tested in unique trial.
Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis | 2012 |
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins | 2012 |
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Guinea Pigs; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Organ Size; Pyrazinamide; Recurrence; Rifamycins; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor.
Topics: Anaerobiosis; Antitubercular Agents; Colony Count, Microbial; Drug Resistance, Bacterial; Humans; Microbial Viability; Molecular Docking Simulation; Mutant Proteins; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases | 2013 |
Rv0132c of Mycobacterium tuberculosis encodes a coenzyme F420-dependent hydroxymycolic acid dehydrogenase.
Topics: Amino Acid Sequence; Antitubercular Agents; Bacterial Proteins; Cell Wall; Gene Expression; Humans; Kinetics; Molecular Sequence Data; Mycobacterium tuberculosis; Mycolic Acids; Nitroimidazoles; Oxidoreductases; Riboflavin; Sequence Alignment; Sequence Homology, Amino Acid; Substrate Specificity | 2013 |
LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study.
Topics: Animals; Chromatography, Liquid; Drug Interactions; Fluoroquinolones; Limit of Detection; Metronidazole; Moxifloxacin; Nitroimidazoles; Plasma; Pyrazinamide; Rats; Tandem Mass Spectrometry | 2014 |
Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis.
Topics: Animals; Caco-2 Cells; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Retrospective Studies; Tuberculosis | 2014 |
PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Isoniazid; Latent Tuberculosis; Lung; Mice; Mice, Inbred C3H; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin | 2014 |
In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Caco-2 Cells; Cell Line, Tumor; Disease Models, Animal; Drug Interactions; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis | 2015 |
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis | 2015 |
A novel molecule with notable activity against multi-drug resistant tuberculosis.
Topics: Antitubercular Agents; Cytochrome P-450 Enzyme System; Drug Design; Drug Synergism; Glucuronosyltransferase; Half-Life; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Piperazines; Pyridones; Tuberculosis, Multidrug-Resistant | 2015 |
Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Topics: Administration, Oral; Animals; Antitubercular Agents; Biological Availability; Chemistry Techniques, Synthetic; Chronic Disease; Disease Models, Animal; Humans; Male; Mice, Inbred BALB C; Mice, Inbred Strains; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rats, Sprague-Dawley; Structure-Activity Relationship; Tuberculosis | 2015 |
New effective antituberculosis regimens.
Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2015 |
Determination of the antitubercular drug PA-824 in rat plasma, lung and brain tissues by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study.
Topics: Animals; Antitubercular Agents; Brain Chemistry; Chromatography, Liquid; Drug Stability; Female; Linear Models; Lung; Nitroimidazoles; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2015 |
Structural insights of PA-824 derivatives: ligand-based 3D-QSAR study and design of novel PA824 derivatives as anti-tubercular agents.
Topics: Antitubercular Agents; Binding Sites; Drug Design; Models, Chemical; Molecular Conformation; Molecular Docking Simulation; Nitroimidazoles; Quantitative Structure-Activity Relationship | 2015 |
Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Polymorphism, Genetic; Protein Structure, Secondary | 2015 |
Synthesis and anti-tubercular activity of 2-nitroimidazooxazines with modification at the C-7 position as PA-824 analogs.
Topics: Antitubercular Agents; Chemistry Techniques, Synthetic; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Structure-Activity Relationship | 2015 |
Tissue distribution of pretomanid in rat brain via mass spectrometry imaging.
Topics: Animals; Antitubercular Agents; Blood-Brain Barrier; Brain; Female; Nitroimidazoles; Prodrugs; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2016 |
Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.
Topics: Agar; Antitubercular Agents; Biological Assay; Charcoal; Colony Count, Microbial; Coloring Agents; Diarylquinolines; Fluorometry; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Xanthenes | 2015 |
glpx Gene in Mycobacterium tuberculosis Is Required for In Vitro Gluconeogenic Growth and In Vivo Survival.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Carbon; Fatty Acids; Fructose-Bisphosphatase; Gene Deletion; Genes, Bacterial; Gluconeogenesis; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Mycobacterium tuberculosis; Nitroimidazoles; Stress, Physiological; Tuberculosis | 2015 |
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Linezolid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Organophosphates; Oxazoles; Oxazolidinones; Pyrazinamide; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2016 |
Pharmacokinetics and tissue distribution study of PA-824 in rats by LC-MS/MS.
Topics: Administration, Oral; Animals; Chromatography, Liquid; Linear Models; Nitroimidazoles; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tissue Distribution | 2015 |
Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.
Topics: Animals; Antitubercular Agents; Chronic Disease; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Tuberculosis | 2016 |
Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis.
Topics: Administration, Inhalation; Antitubercular Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Fluoroquinolones; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant | 2017 |
Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.
Topics: Animals; Antimony; Antiprotozoal Agents; Cell Differentiation; Cell Line; Host-Pathogen Interactions; Humans; Inhibitory Concentration 50; Leishmania donovani; Macrophages; Mice; Mice, Knockout; Monocytes; Nitroimidazoles; Primary Cell Culture; Stereoisomerism; Tetradecanoylphorbol Acetate | 2017 |
Easier cure for resistant TB.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Baltimore; Clinical Trials as Topic; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; South Africa; Sputum; Treatment Outcome | 2017 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.
Topics: Animals; Antitubercular Agents; Chagas Disease; Disease Models, Animal; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Thiazoles; Tuberculosis | 2017 |
Biopharmaceutic parameters, pharmacokinetics, transport and CYP-mediated drug interactions of IIIM-017: A novel nitroimidazooxazole analogue with anti-tuberculosis activity.
Topics: Animals; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Computer Simulation; Drug Interactions; Humans; Mice, Inbred BALB C; Microsomes, Liver; Nitroimidazoles; Oxazoles | 2017 |
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Pulmonary | 2017 |
Cordyceps sinensis promotes immune regulation and enhances bacteriostatic activity of PA-824 via IL-10 in Mycobacterium tuberculosis disease.
Topics: Animals; Anti-Bacterial Agents; Blotting, Western; Cordyceps; Disease Models, Animal; Flow Cytometry; Immunomodulation; Interleukin-10; Male; Mice; Mice, Inbred CBA; Mycobacterium tuberculosis; Nitroimidazoles; Real-Time Polymerase Chain Reaction; Tuberculosis, Pulmonary | 2017 |
Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Autophagy; Cell Line, Tumor; Disease Models, Animal; Escherichia coli; Female; Humans; Macrophages; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium bovis; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Phenanthrolines; Structure-Activity Relationship; THP-1 Cells; Tuberculosis, Multidrug-Resistant | 2017 |
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Molecular Structure; Nitroimidazoles; Small Molecule Libraries; Structure-Activity Relationship; Trypanosomiasis, African | 2018 |
Novel Pyrimidines as Antitubercular Agents.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Design; Drug Stability; Female; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Pyrimidines; Solubility; Structure-Activity Relationship; Tuberculosis | 2018 |
Drug-Drug Interactions Between PA-824 and Darunavir Based on Pharmacokinetics in Rats by LC-MS-MS.
Topics: Animals; Chromatography, Liquid; Darunavir; Drug Interactions; Linear Models; Nitroimidazoles; Rats; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions.
Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Tolerance; Fluoroquinolones; Genetic Fitness; Genotype; Humans; Lipid Metabolism; Lipids; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin | 2018 |
Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824).
Topics: Antitubercular Agents; Gas Chromatography-Mass Spectrometry; Humans; Metabolic Networks and Pathways; Metabolome; Metabolomics; Mycobacterium Infections, Nontuberculous; Mycobacterium smegmatis; Nitroimidazoles | 2018 |
Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.
Topics: Adolescent; Adult; Antitubercular Agents; Female; Humans; Male; Middle Aged; Models, Theoretical; Monte Carlo Method; Nitroimidazoles; Tuberculosis, Pulmonary; Young Adult | 2018 |
Enhanced brain penetration of pretomanid by intranasal administration of an oil-in-water nanoemulsion.
Topics: Administration, Intranasal; Animals; Brain; Chromatography, Liquid; Drug Delivery Systems; Emulsions; Male; Nanoparticles; Nitroimidazoles; Rats; Rats, Sprague-Dawley; Solid Phase Extraction; Tuberculosis, Meningeal | 2018 |
Coenzyme F
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Glucosephosphate Dehydrogenase; Ligases; Methanobacteriaceae; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Polyglutamic Acid; Recombinant Proteins; Riboflavin; Tetrahydrofolates | 2018 |
3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
Topics: Antitubercular Agents; Drug Development; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitroimidazoles; Quantitative Structure-Activity Relationship | 2019 |
Rational design of coumarin derivatives as antituberculosis agents.
Topics: Antitubercular Agents; Cell Survival; Coumarins; Drug Design; HeLa Cells; Humans; MCF-7 Cells; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Signal Transduction; Structure-Activity Relationship; THP-1 Cells | 2018 |
Effect of Moxifloxacin plus Pretomanid against
Topics: Antitubercular Agents; Drug Combinations; Drug Interactions; Drug Resistance, Fungal; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles | 2019 |
Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.
Topics: Animals; Antiparasitic Agents; Antitubercular Agents; Caco-2 Cells; Drug Design; Drug Evaluation, Preclinical; Drug Stability; Entamoeba histolytica; Giardia lamblia; Humans; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Nitroimidazoles; Structure-Activity Relationship | 2018 |
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2019 |
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Ion Concentration; Hypoxia; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis | 2019 |
Chalcogen OCF
Topics: Animals; Dogs; Humans; Hydrophobic and Hydrophilic Interactions; Madin Darby Canine Kidney Cells; Microsomes, Liver; Molecular Structure; Nitroimidazoles; Organoselenium Compounds; Riluzole; Sulfides | 2019 |
Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid.
Topics: Aerobiosis; Antitubercular Agents; Cell Wall; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Genome; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; RNA, Bacterial; Sequence Analysis, RNA | 2019 |
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.
Topics: Antitubercular Agents; Biological Availability; Clinical Trials as Topic; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Lopinavir; Male; Nitroimidazoles; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Markov Chains; Nitroimidazoles; Prevalence; Pyrazinamide; Rifampin; South Africa; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
BPaL approved for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Drug Approval; Drug Therapy, Combination; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2019 |
Breakthrough in the treatment of drug-resistant tuberculosis.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2019 |
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Mathematics; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis | 2020 |
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative?
Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 2019 |
Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2021 |
Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Oxazoles; Polymorphism, Genetic; Protein Engineering | 2020 |
Tuberculosis treatment: one-shot approach or cascade of regimens?
Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 2020 |
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
New drugs 2020, part 3.
Topics: Aminophenols; Antibodies, Monoclonal, Humanized; Azabicyclo Compounds; Benzodioxoles; beta-Cyclodextrins; Cilastatin; Drug Approval; Drug Combinations; Ethinyl Estradiol; Genetic Vectors; Humans; Imipenem; Indoles; Nitroimidazoles; Pregnanolone; Pregnenediones; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Retinoids; United States; United States Food and Drug Administration | 2020 |
Mutations in
Topics: Animals; Antitubercular Agents; Mice; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles | 2020 |
An Exposure-Response Perspective on the Clinical Dose of Pretomanid.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant | 2020 |
Pretomanid for the treatment of pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2020 |
A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients.
Topics: Adult; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Nitroimidazoles; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tuberculosis, Pulmonary | 2021 |
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.
Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration | 2021 |
Mesoporous Silica Nanoparticles Improve Oral Delivery of Antitubercular Bicyclic Nitroimidazoles.
Topics: Amines; Animals; Antitubercular Agents; Drug Carriers; Mice; Nanoparticles; Nitroimidazoles; Organophosphonates; Silicon Dioxide | 2022 |
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing | 2021 |
Topics: Humans; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Nontuberculous Mycobacteria | 2022 |
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Georgia; Humans; Linezolid; Nitroimidazoles; Philippines; South Africa; Tuberculosis, Multidrug-Resistant | 2021 |
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Granuloma; Humans; Linezolid; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Nitroimidazoles | 2022 |
Delamanid or pretomanid? A Solomonic judgement!
Topics: Antitubercular Agents; Diarylquinolines; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis | 2022 |
Molecular dynamic assisted investigation on impact of mutations in deazaflavin dependent nitroreductase against pretomanid: a computational study.
Topics: Antitubercular Agents; Ligands; Molecular Dynamics Simulation; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases | 2023 |
Male reproductive hormones in patients treated with pretomanid.
Topics: Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Nitroimidazoles; Testosterone; Tuberculosis, Multidrug-Resistant | 2022 |
Evidence of safety for pretomanid and male reproductive health.
Topics: Antitubercular Agents; Humans; Male; Nitroimidazoles; Reproductive Health | 2022 |
Pretomanid in the Treatment of Patients with Tuberculosis in the United States.
Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant; United States | 2022 |
Development and validation of stability-indicating -HPLC method for the determination of related substances in novel nitroimidazole antituberculosis drug pretomanid: Robustness study by Design-Expert and application to stability studies.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Stability; Humans; Nitroimidazoles; Reproducibility of Results | 2022 |
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2022 |
The
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2022 |
Dynamic
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Humans; Linezolid; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Rabbits; Tuberculosis, Meningeal; Tuberculosis, Multidrug-Resistant | 2022 |
Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Rifamycins; Tuberculosis | 2023 |
Pretomanid-resistant tuberculosis.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling.
Topics: Animals; Antitubercular Agents; Humans; Lung; Mice; Nitroimidazoles; Pyrazinamide; Tuberculosis | 2023 |
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Nitroimidazoles; Oxazolidinones; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2023 |
DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid.
Topics: Alcohol Oxidoreductases; Antitubercular Agents; Cell Wall; Drug Resistance; Kinetics; Molecular Targeted Therapy; Mycobacterium tuberculosis; NAD; Nitroimidazoles; Prodrugs; Spectrophotometry | 2023 |
Discovery and characterization of antimycobacterial nitro-containing compounds with distinct mechanisms of action and
Topics: Animals; Bacterial Load; Mice; Nitro Compounds; Nitrofurans; Nitroimidazoles | 2023 |
The Implementation of a Pretomanid-Based Treatment Regimen for Multidrug-Resistant Tuberculosis: A Case Series.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant | 2023 |